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Introduction
Pregnancy loss is a common obstetric complication and
affects > 30% of conception.1 The majority of these
losses occur in the 1st trimester, including spontaneous
abortion, anembryonic gestation and embryonic or
fetal death.2 The prevalence of early pregnancy failure
was 2.8% in a study involving 17,810 women at
10–13 weeks’ gestation, and anembryonic pregnancies
accounted for 37.5% of the pregnancies lost.3 Loss
before the development of an embryo is more likely
to be associated with genetic abnormalities than those
later in gestation,4 and imparts a considerable influ-
ence on recurring risk in subsequent pregnancies.
Anembryonic pregnancy is defined as a gestational
sac (GS) containing no fetal pole with a mean diam-
eter ≥ 15 mm, or a GS < 15 mm not showing any
growth in 7 days.5,6 Dilatation and curettage has been
the primary treatment option for early pregnancy loss
in many countries since it was first introduced into
clinical practice in the 1930s.7 However, the risks of
uterine evacuation, including sepsis, hemorrhage and
anesthesia-related complications, have always been of
concern to patients. In 1995, Nielsen and Hahlin con-
ducted a small randomized study of expectant and sur-
gical management of early nonviable pregnancies, which
suggested that the outcomes were similar, including
complications and the need for a second or emergent
curettage.8 Additional studies have supported the role
of expectant management as a treatment option in early
pregnancy loss; however, reported success rates have
ranged widely from 25% to 76%.9,10
According to Luise et al’s study in 2002, expectant
management in patients with anembryonic pregnancies
had a less favorable success rate compared to patients
with incomplete abortion or embryonic fetal death.10
Patients with failure of expectant management eventu-
ally required surgical evacuation to remove the products
of conception. In contrast, based on a randomized trial
conducted by Wieringa-de Waard et al, up to 40% of
surgeries can be avoided by a waiting period of 7 days,
which could be offered to well-informed women.6
Patients were willing to accept the waiting period with
adequate counseling and help.
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Management of anembryonic pregnancy
The success rate of surgical treatment has been
superior to that of expectant management in both
reviewed literature and clinical practice. However,
expectant management can be justified as an alternative
treatment option if the success rate can reach 80%.
The purpose of this study was to determine whether
or not expectant management with a 3-week waiting
period is an effective and safe option for women with
anembryonic pregnancy, and if outcomes differ from
those of surgical evacuation.
Methods
Subjects
Women presenting to the outpatient clinic and emer-
gency department of Hsinchu Cathay General Hospital
(CGH) in Taiwan between July 1, 2008 and June 30,
2009 with anembryonic pregnancy were included in
the study. The trial was approved by the Institutional
Review Board of Hsinchu CGH (number CT 9813),
and all of the subjects gave informed consent.
Diagnosis of anembryonic pregnancy was made
when, as seen on transvaginal ultrasound, the mean
diameter of the GS was ≥ 15 mm without a visible
embryo or the GS was < 15 mm and with no growth in
7 days.5,6 All of the sonographic scans were performed
by obstetricians in Hsinchu CGH using a 6.5-MHz
transducer (Aloka Co. Ltd., Tokyo Japan). Endometrial
thickness was measured in the sagittal plane from the
interface of the endometrium and myometrium across
the uterine cavity.
The inclusion criteria were hemodynamic stability,
temperature < 37.5°C in the past 24 hours, no history
of current serious systemic disease, ≥ 20 years of age,
singleton pregnancy, no intrauterine device present,
and no contraindication to the use of prostaglandin and
ergonovine. Patients were excluded if they were expe-
riencing severe pain, fever or heavy bleeding requiring
immediate surgery. Patients could opt out of the study
at any time on request.
Protocol
Patients who met the inclusion criteria were informed
of the risks and benefits of expectant management and
surgical treatment. Patients then elected expectant or
surgical management. The patients in the expectant
management group were seen in the outpatient clinic
on days 14 and 21 for reevaluation before the prod-
ucts of conception were expelled. Once the tissue was
passed, patients returned to the outpatient clinic in 7
days and ultrasonography was performed to determine
if there was any retained tissue in the uterine cavity. 
If there was evidence of retained tissue or if the endome-
trial lining was ≥ 15 mm, then a 200-μg tablet of miso-
prostol was given 3 times a day orally for the next 3 days
(maximum dose, 1,800 μg). Patients with retained tissue
were considered a treatment failure.
If the expulsion was still incomplete after taking
misoprostol or if expulsion failed to occur after 21 days
of expectant management, then surgical uterine evacu-
ation was performed. Patients had 1 scheduled follow-
up visit in 7 days, and ultrasonography was performed
to assess the endometrial lining.
The symptoms and signs during the waiting period
of expectant management before spontaneous loss
were thoroughly explained to the patients in the expec-
tant group, who also received a contact phone num-
ber in case further care or information was necessary.
Emergent admission and surgery were arranged if
necessary.
Outcome measures
The primary outcome measure was complete expul-
sion of the products of conception within 21 days after
the diagnosis of anembryonic pregnancy was made.
Treatment success was defined as endometrial thick-
ness < 15 mm in the follow-up visit after spontaneous
abortion or surgical curettage had been performed.
For women with incomplete expulsion or endometrial
thickness ≥ 15 mm in both groups, we also determined
whether or not additional management with medica-
tion improved the overall success rate. The secondary
outcomes assessed were the number of patients requir-
ing a second curettage and immediate surgery due to
bleeding > 500 mL, and the incidence of pelvic in-
flammatory disease within 4 weeks after evacuation of
uterus and pain severity.
Patients were offered nonsteroidal anti-inflammatory
drugs for pain relief. If the pain was unbearable, they
were required to return to the clinic, where narcotic
or opiate medications were provided if necessary.
Infection was diagnosed if patients presented with
lower abdominal pain or leukorrhea, and 1 of any of the
following criteria was met: temperature >38°C, white
blood cell count ≥ 11,000/mm3, and administration
of antibiotics within 4 weeks of expulsion, whether by
expectant management or surgical evacuation.
Statistical analysis
Statistical analysis was performed using SPSS version
13 (SPSS Inc., Chicago, IL, USA). Student’s t test,
Fisher’s exact test and χ2 test were used to analyze the
differences in patient characteristics and outcomes. 
A p value < 0.05 was considered to indicate statistical
significance.
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Results
A total of 121 eligible women who presented to
Hsinchu CGH between July 1, 2008 and June 30,
2009 were enrolled into this study (Figure 1). There
were no significant differences in patient characteris-
tics between the expectant and surgical management
groups except for the size of the GS (Table 1). The
mean size of the GS in the expectant management
group was 2.7 cm, versus 2.1 cm in the surgical man-
agement group.
Of the enrolled women, 76 underwent surgical
evacuation and 45 elected to have expectant manage-
ment. The overall success rate of expectant manage-
ment was 83.3%, compared with 97.3% for surgical
evacuation.
Of the 45 women in the expectant management
group, 8 withdrew from the study and were excluded
from the analysis. Five of these 8 women dropped out
on day 7, and the other 3 dropped out on days 6, 9 and
16. All 8 patients subsequently received uterine curet-
tage. Also, 1 patient did not return after being allo-
cated to the expectant management group, so she was
excluded as well. In the 36 women who were included
for analysis, 22 experienced spontaneous loss within 14
days of diagnosis and 8 within 21 days. Of the remain-
ing 6 patients, 2 expelled the products of conception
on days 3 and 4, respectively, but an endometrial
thickness ≥ 15 mm was revealed by ultrasound when
they returned to the clinic. These 2 patients experi-
enced vaginal bleeding for more than 14 days and were
administered oral misoprostol, after which the bleeding
stopped within 7 days. In the last 4 patients, ultrasound
revealed visible GS on day 21. These 4 women only
experienced minimal vaginal spotting; they underwent
surgical evacuation and were classified as treatment
failure of expectant management.
In the surgical management group, 2 patients re-
quired a second curettage due to persistent vaginal bleed-
ing for > 21 days (Table 2) despite the administration
Expectant management
(n = 45)
Eligible and consented
(n = 121)
By patient’s preference
Allocation
Expectant
management
(n = 36)
Successful
treatment within 
14 days (n = 22)
Successful treatment
within 21 days
(n = 30)
Failure and arranged
evacuation (n = 4)
EM ≥ 15 mm
Use of misoprostol
(n = 2)
Successful
treatment
(n = 74)
A second
curettage
(n = 2)
Treatment
0–14 days
0–21 days
Dropped out
for surgery
(n = 8)
Loss to
follow-up
(n = 1)
Curettage
(n = 76)
All 76 patients
underwent surgery
Follow-up
Analysis
Figure 1. The allocation of patients based on their preferences. EM = endometrial thickness.
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of misoprostol. Pathological reports revealed residual
gestational tissue, and bleeding only stopped on days
5 and 6 after the second operation.
The presence of vaginal bleeding before treatment
had no significant effect on the success of expulsion;
47.2% (17/36) of patients in the expectant manage-
ment group had vaginal spotting, but the success rate
reached 83.3% (30/36; p = 0.662, Fisher’s exact test).
Three patients with failed expectant management had
intermittent vaginal bleeding, but the tissue was not
expelled within the 3-week waiting period.
No woman in either group required blood trans-
fusion. No patient in the expectant management group
required more than nonsteroidal anti-inflammatory
drugs for pain relief, and none of them underwent
emergent curettage because of intolerable pain or heavy
bleeding. Five patients in the surgical group experi-
enced lower abdominal pain after uterine curettage
and received antibiotic treatment. The incidences 
of pelvic inflammatory disease were 6.5% and 2.5% 
in the surgical and expectant management groups,
respectively.
Discussion
The causes of pregnancy loss vary with gestational
age. The expression “blighted ovum” has been replaced
Table 1. Patients’ characteristics*
Surgical management Expectant management
p†
(n = 76) (n = 36)
Age (yr) 32.7 ± 0.5 (26–39) 32.9 ± 0.48 (24–42) NS
Parity
0 43 (56.5) 22 (59.4) NS
≥ 1 15 (40.6) 33 (43.5) NS
Previous miscarriage 21 (27.6) 3 (8.1) NS
GS size (cm) 2.1 ± 0.1 2.7 ± 0.2 0.02
Time to return to clinic (d) 6.7 ± 0.3 8.2 ± 0.5 NS
Successful treatment
EM < 15 mm 74 (97.3) 30 (83.3) 0.013
Vaginal bleeding present 23 (30.2) 17 (47.2) NS
EM thickness at follow-up (mm) 8 ± 2 6 ± 5 NS
*Data presented as mean ± standard deviation (range) or n (%) or mean ± standard deviation; †success rate was analyzed by Fisher’s exact test and differ-
ences in patient characteristics analyzed by c2 test. GS = gestational sac; EM = endometrial thickness; NS = not significant.
Table 2. Outcomes*
Surgical management Expectant management 
(n = 76) (n = 36)
Successful treatment with EM < 15 mm 74 (97.3) 30 (83.3)
Treatment with medication due to 2 (2) 2 (6.2)
EM ≥ 15 mm after abortion
Successful treatment with medication† 4 (97.3) 32 (88.85)
Second curettage 2 (2) 0
Emergent curettage 0 0
Failure of expulsion – 4 (11.1)
Complications
Hemorrhage > 500 mL 0 0
Pain requiring opiates or narcotics 0 0
Infection within 4 wk of abortion 5 (6.5) 1 (2.7)
Uterine perforation 0 –
Bleeding status before treatment 23 (30.2) 17 (47.2)
Time to spontaneous abortion (d)‡ – 9.15 ± 2.9 (2–21)
*Data presented as n (%) or mean ± standard deviation (range); †success rate was assessed after patients with incomplete abortion or EM ≥ 15 mm took
misoprostol; ‡from time of diagnosis of anembryonic pregnancy. EM = endometrial thickness.
J Chin Med Assoc • March 2010 • Vol 73 • No 3154
Y.T. Huang, et al
with anembryonic or preembryonic pregnancy loss,
defined in terms of developmental biology, and possibly
occurs when there are genetic problems.11 Recently, the
management of early pregnancy loss has changed from
a surgical approach to conservative treatment. The rate
of spontaneous expulsion varies depending on the type
of miscarriage; with anembryonic pregnancy, a lower suc-
cess rate may be due to an intact sac and closed cervix.12
Rates as low as 24.7% have been reported by Jurkovic
et al,9 whereas Nielsen and Hahlin reported the success
rates of expectant management to be 91% for incom-
plete miscarriage, 76% for missed abortion, and 66%
for anembryonic pregnancy.8 In our study, the success
rate by day 14 was 61.1%, consistent with the study of
Nielsen and Hahlin. Our success rate reached 83.3%
by day 21, indicating that a longer waiting period can
reduce the need for surgical evacuation.6
Successful outcome in the current study was defined
as an endometrial thickness < 15 mm without retained
products of conception after natural expulsion or sur-
gical evacuation. If we were to include the 2 patients
with endometrial thickness ≥ 15 mm who took miso-
prostol (after which their bleeding stopped) and the
patient with endometrial thickness < 15 mm within
10 days in the expectant group, the overall success rate
would be 88.8%. In that case, successful treatment was
considered as no need for uterine curettage. According
to the systematic review of 18 studies by Geyman 
et al,13 expectant management for 1st trimester preg-
nancy loss has an overall success rate of 93%. The 
surgical success rate reported by Creinin et al14 was
98%, which is consistent with our finding.
In Zhang et al’s study of 1st trimester pregnancy
failure including anembryonic gestation, embryonic or
fetal death, incomplete abortion or inevitable sponta-
neous abortion, misoprostol 800 mg vaginally was
given to the women on day 1 and a second dose on day
3 if expulsion was incomplete. By day 3, 71% had expe-
rienced complete expulsion; by day 8, the success rate
had reached 84%.15 Immediate administration of med-
ication saves waiting time and its success rate is similar
to that of expectant management.
In our study, we used a cut-off value for endome-
trial thickness of < 15 mm to define treatment success.
However, there is evidence to suggest that 15 mm is
too stringent.10,15–17 Patients with endometrial thick-
ness 15–30 mm after misoprostol treatment usually
expel the products of conception completely without
complications.17 Creinin et al analyzed 80 women
with early pregnancy loss who were treated with miso-
prostol, and suggested that there was no obvious rela-
tionship between increasing endometrial thickness and
the need for surgical intervention as none of their
patients with endometrial thickness ≥ 15 mm required
surgical intervention.17 Based on literature reports, it
would appear that it was not necessary to use miso-
prostol in our 2 patients with endometrial thickness
≥ 15 mm as spontaneous resolution would likely have
occurred. However, the medication may reduce the
length of vaginal bleeding. In our surgical management
group, 2 patients underwent a second curettage due to
prolonged bleeding. When we compared the intrauter-
ine sonographic pattern of these 4 women (2 in the
expectant management group; 2 in the surgical man-
agement group) with endometrial thickness ≥ 15 mm,
the echogenicity was obviously more heterogeneous
in the surgical management patients. Bleeding persisted
despite the administration of misoprostol. Operative
reintervention is indicated in symptomatic abnormal
endometrial content.18
In this study, mean GS was 2.7 cm and 2.1 cm in
the expectant and surgical management groups, respec-
tively. Although GS size was a significantly different
factor in the patient characteristics of the 2 groups,
the group allocation in the study was based on the
requests of the patients rather than on randomization.
The 4 patients who had expectant management fail-
ure had GS > 3 cm in diameter (3.5, 3.28, 3.54 and
3.1 cm). The presence of a GS that is deformed or flat-
tened, with largest diameter >5cm without a detectable
embryo, is often an indicator of miscarriage.19 Due to
our small sample size, we could not determine if GS
> 3 cm is associated with a higher failure rate of spon-
taneous expulsion.
There was no increase in complications such as
infection or bleeding in the expectant management
group, or in the 4 patients with treatment failure during
the 3-week waiting period. The 8 patients who dropped
out of the expectant management group did so because
they lost patience and were tired of waiting. With thor-
ough explanation and adequate consultation, the waiting
time for tissue expulsion might be extended on their
preference. Retained tissue in the endocervical canal
with pain and bleeding sometimes occur in patients
managed expectantly, but this did not occur in our
study group. In most cases, the tissue can be removed
with ring forceps without further treatment.17 We assumed
that anembryonic pregnancy often presents with an
empty sac, or only a minimal fetal pole, which allows the
small amount of tissue to pass smoothly.
In conclusion, our results indicate that expectant
management with a 3-week waiting period is a safe and
effective option with a low risk of infection and hem-
orrhage for the management of anembryonic preg-
nancy in early gestation. The success rate is higher than
previously reported, though lower than for surgical
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curettage. Adequate counseling and help are important
for women who choose expectant management of preg-
nancy loss as it is difficult to predict the exact time
when expulsion may occur and so the optimal follow-
up time is not yet standardized.
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